Amgen
Amgen Inc. operates as one of the world's leading independent biotechnology companies, discovering, developing, manufacturing and delivering innovative medicines to treat some of the world's most challenging diseases. The company trades on the NASDAQ under the ticker symbol AMGN and maintains its corporate website at… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Amgen does
In the company’s own words
Amgen Inc. operates as one of the world's leading independent biotechnology companies, discovering, developing, manufacturing and delivering innovative medicines to treat some of the world's most challenging diseases. The company trades on the NASDAQ under the ticker symbol AMGN and maintains its corporate website at www.amgen.com.
The company operates in a single reportable segment focused on human therapeutics. Amgen's product portfolio spans multiple therapeutic areas including cardiovascular disease, oncology, bone health, inflammation, and rare diseases. Major marketed products include Repatha for cardiovascular risk reduction, Prolia and XGEVA for bone health, ENBREL for rheumatoid arthritis and psoriasis, Otezla for psoriatic disease, TEZSPIRE for asthma and chronic rhinosinusitis, BLINCYTO for leukemia, and TEPEZZA for thyroid eye disease. The company also markets biosimilar versions of competitor products including WEZLANA and BKEMV. In 2025, the company generated total product sales of approximately $35.1 billion, with the United States representing 73 percent of revenues and rest of world accounting for 27 percent.
Amgen maintains a global presence in approximately 100 countries with significant sales and marketing operations concentrated in the United States and Europe. The company supplements its internal manufacturing network with third-party contract manufacturers and operates state-of-the-art biomanufacturing facilities in North Carolina and Ohio alongside traditional facilities in California, Rhode Island, Puerto Rico, and internationally in Ireland, the Netherlands, and Singapore. The company was incorporated in California in 1980 and became a Delaware corporation in 1987, having helped launch the biotechnology industry more than 45 years ago.
The company's competitive advantages include its extensive expertise in manufacturing complex biologics, a robust pipeline of potential first-in-class medicines, and established relationships with healthcare providers and payers globally. Amgen distributes substantially all U.S. sales through three major pharmaceutical wholesalers that collectively account for 77 percent of worldwide gross revenues. The company invests billions annually in research and development to advance its pipeline and maintain its position as an innovation leader in the biopharmaceutical industry.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- THOUSAND OAKS, CA
- Fiscal year end
- December
- CIK
- 318154
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Amgen — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Amgen · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Amgen’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Amgen’s bonds, as funds hold them
Funds report holding 41 issues of Amgen’s debt, $8.56B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.63%, maturing 2026 to 2063.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Amgen and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Amgen's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Amgen's last four quarterly filings that the numbers alone won't show?”